Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
1.69
Dollar change
+0.02
Percentage change
1.20
%
IndexRUT P/E- EPS (ttm)-0.67 Insider Own18.41% Shs Outstand36.67M Perf Week-3.98%
Market Cap74.56M Forward P/E- EPS next Y-0.92 Insider Trans0.15% Shs Float36.00M Perf Month8.33%
Income-25.42M PEG- EPS next Q-0.17 Inst Own25.82% Short Float5.51% Perf Quarter27.07%
Sales0.00M P/S- EPS this Y18.98% Inst Trans-31.84% Short Ratio4.41 Perf Half Y-10.58%
Book/sh0.37 P/B4.59 EPS next Y-36.80% ROA-76.71% Short Interest1.98M Perf Year-47.02%
Cash/sh0.47 P/C3.60 EPS next 5Y- ROE-140.78% 52W Range1.05 - 5.85 Perf YTD-18.75%
Dividend Est.- P/FCF- EPS past 5Y-7.37% ROI-89.76% 52W High-71.11% Beta1.65
Dividend TTM- Quick Ratio3.49 Sales past 5Y125.00% Gross Margin-72219.03% 52W Low60.95% ATR (14)0.14
Dividend Ex-Date- Current Ratio3.50 EPS Y/Y TTM-18.12% Oper. Margin-1945924.37% RSI (14)47.12 Volatility8.25% 8.22%
Employees41 Debt/Eq1.02 Sales Y/Y TTM-99.99% Profit Margin-2121649.00% Recom1.00 Target Price10.50
Option/ShortYes / Yes LT Debt/Eq0.79 EPS Q/Q13.36% Payout- Rel Volume1.39 Prev Close1.67
Sales Surprise672.40% EPS Surprise0.06% Sales Q/Q- EarningsNov 13 AMC Avg Volume449.94K Price1.69
SMA20-4.40% SMA50-5.17% SMA200-14.54% Trades Volume627,485 Change1.20%
Date Action Analyst Rating Change Price Target Change
Mar-01-21Initiated Northland Capital Outperform $10
Feb-03-20Downgrade Oppenheimer Outperform → Perform
Feb-13-24 07:00AM
Jan-26-24 09:22AM
Jan-16-24 07:00AM
Dec-15-23 08:17AM
Nov-14-23 10:38AM
04:05PM Loading…
Nov-13-23 04:05PM
Nov-06-23 08:00AM
Nov-02-23 07:00AM
Oct-30-23 03:52PM
07:00AM
Oct-09-23 07:00AM
Sep-21-23 08:00AM
Sep-07-23 08:00AM
Aug-24-23 06:47PM
Aug-16-23 06:00AM
09:05AM Loading…
Aug-14-23 09:05AM
Aug-11-23 06:08AM
Aug-10-23 04:05PM
Aug-09-23 08:00AM
Aug-07-23 08:00AM
Aug-03-23 08:00AM
Jun-26-23 08:00AM
Jun-06-23 09:00AM
Jun-01-23 08:00AM
May-12-23 06:04AM
May-11-23 04:05PM
May-08-23 04:39PM
08:17AM
08:02AM
08:00AM
02:32AM Loading…
02:32AM
May-04-23 08:00AM
Apr-24-23 08:00AM
Apr-05-23 07:46PM
Mar-30-23 04:05PM
Mar-23-23 08:00AM
Feb-28-23 04:05PM
Feb-22-23 06:08AM
Feb-15-23 09:51AM
Jan-12-23 12:47PM
08:00AM
Dec-20-22 08:00AM
Dec-13-22 08:00AM
Dec-08-22 08:00AM
Nov-29-22 08:00AM
Nov-23-22 04:05PM
Nov-13-22 07:04AM
Nov-10-22 04:05PM
Nov-03-22 08:00AM
Oct-21-22 08:00AM
Oct-20-22 08:00AM
Oct-05-22 02:50PM
Sep-30-22 08:00AM
Sep-07-22 08:00AM
Sep-06-22 08:00AM
Aug-10-22 04:05PM
Aug-04-22 08:00AM
Jul-27-22 08:00AM
Jul-18-22 08:00AM
Jul-07-22 08:00AM
Jul-06-22 08:00AM
Jun-29-22 08:53AM
Jun-09-22 10:09AM
08:00AM
Jun-07-22 08:00AM
May-15-22 08:06AM
May-12-22 04:05PM
May-05-22 08:00AM
Apr-20-22 08:00AM
Apr-19-22 08:00AM
Apr-03-22 01:46PM
Mar-31-22 01:17PM
Mar-28-22 04:05PM
Mar-21-22 08:00AM
Mar-15-22 08:00AM
Mar-04-22 09:07AM
07:00AM
Feb-13-22 06:29AM
Feb-08-22 08:00AM
Feb-07-22 08:30AM
Dec-10-21 05:46AM
Nov-17-21 12:00PM
Nov-10-21 06:45PM
04:05PM
Nov-08-21 08:00AM
Nov-05-21 03:25PM
Nov-04-21 04:05PM
08:00AM
07:34AM
03:14AM
Nov-01-21 03:23PM
Oct-29-21 05:28PM
Oct-28-21 07:40AM
Oct-26-21 11:00AM
Oct-25-21 02:31PM
12:11PM
10:17AM
08:00AM
Oct-05-21 08:21AM
Oct-03-21 09:00AM
Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The firm is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression, and mydriasis. The company was founded by Sean Ianchulev on March 12, 2014 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rowe Michael MChief Executive OfficerDec 04Buy1.364,8906,65032,927Dec 05 04:54 PM
Strahlman Ellen RDirectorSep 29Buy1.684,8208,09875,113Oct 02 10:04 AM
Rowe Michael MChief Executive OfficerSep 19Buy1.661,4002,32428,037Sep 19 05:17 PM
Rowe Michael MChief Executive OfficerSep 15Buy1.751,1371,99026,637Sep 19 05:17 PM
Grant Stuart M.10% OwnerAug 17Buy1.8730,00056,1005,269,998Aug 17 03:16 PM
Grant Stuart M.10% OwnerAug 16Buy1.9145,00085,8155,239,998Aug 17 03:16 PM
GANDOLFO JOHN PChief Financial OfficerMay 31Buy2.792,0005,5808,000May 31 06:31 PM
MATHER CHARLES E IVDirectorMay 26Buy2.493,0007,47077,544May 30 10:13 AM
Kern BrenChief Operating OfficerMay 26Buy2.732,5006,8252,500May 31 10:48 AM
Grant Stuart M.10% OwnerMay 25Buy2.6588,247233,8555,194,998May 26 12:55 PM
Strahlman Ellen RDirectorMay 23Buy3.1010,00030,97653,052May 25 04:45 PM
Rowe Michael MChief Executive OfficerMay 01Option Exercise2.7210,00027,20025,500May 01 08:47 PM
Ianchulev TsontchoDirectorMay 01Sale5.5090,000495,000331,211May 02 07:38 PM
Ianchulev TsontchoDirectorApr 27Sale5.0060,000300,000421,211May 01 12:43 PM
Ianchulev TsontchoDirectorApr 14Sale4.5040,000180,000481,211Apr 17 09:05 AM
Ianchulev TsontchoDirectorApr 11Sale4.0040,000160,000521,211Apr 12 06:39 PM
Ianchulev TsontchoDirectorMar 31Sale3.5040,000140,000561,211Apr 03 08:20 PM